Analyst Ratings For Lexicon Pharmaceuticals (NASDAQ:LXRX)
Today, Lexicon Pharmaceuticals (NASDAQ:LXRX) stock was downgraded by Needham & Company LLC from Buy to Hold.
Some recent analyst ratings include
- 2/23/2018-Needham & Company LLC was Downgraded by analysts at Needham & Company LLC from a “Buy ” rating to a ” Hold” rating.
- 2/14/2018-JPMorgan Chase & Co. was Downgraded by analysts at JPMorgan Chase & Co. from a “Neutral ” rating to a ” Underweight” rating. They now have a $10.00 price target on the stock, up previously from $15.00 .
- 11/30/2017-Wedbush Reiterated Rating of Outperform.
- 8/1/2017-Cowen Reiterated Rating of Hold.
- On 11/17/2017 Public Equities L.P. Invus, Director, bought 180,727 with an average share price of $10.11 per share and the total transaction amounting to $1,827,149.97.
- On 11/15/2017 Lonnel Coats, CEO, bought 10,000 with an average share price of $9.91 per share and the total transaction amounting to $99,100.00.
- On 11/14/2017 Jeffrey L Wade, EVP, bought 2,000 with an average share price of $9.48 per share and the total transaction amounting to $18,960.00.
- On 11/14/2017 Public Equities L.P. Invus, Director, bought 575,946 with an average share price of $9.64 per share and the total transaction amounting to $5,552,119.44.
- On 11/10/2017 Public Equities L.P. Invus, Director, bought 145,680 with an average share price of $9.74 per share and the total transaction amounting to $1,418,923.20.
- On 9/15/2017 Lonnel Coats, Insider, bought 30,000 with an average share price of $12.54 per share and the total transaction amounting to $376,200.00.
- On 9/15/2017 Sam L Barker, Director, bought 1,000 with an average share price of $12.50 per share and the total transaction amounting to $12,500.00.
Recent Trading Activity for Lexicon Pharmaceuticals (NASDAQ:LXRX)
Shares of Lexicon Pharmaceuticals closed the previous trading session at with 608200 shares trading hands.